Prolactinomas and pregnancy.
Molitch
Mark E
ME
Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. molitch@northwestern.edu
D000634:Aminoquinolines / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D047108:Embryonic Development / Q000187:drug effects / Q000502:physiology; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010911:Pituitary Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D011256:Pregnancy Outcome / Q000453:epidemiology; D015175:Prolactinoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D018491:Dopamine Agonists; D004873:Ergolines; C046650:quinagolide; D000077465:Cabergoline